Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care

The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. Discoveries in the laboratory inform clinical trials which are the basis for improving the standard of care and are also the backbone for quali...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortimer, Joanne E., Kruper, Laura, Cianfrocca, Mary, Lavasani, Sayeh, Liu, Sariah, Tank-Patel, Niki, Sedrak, Mina, Smith, Wade, Stewart, Daphne, Waisman, James, Yeon, Christina, Wang, Tina, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355741/
https://www.ncbi.nlm.nih.gov/pubmed/32599960
http://dx.doi.org/10.3390/jcm9061984
Descripción
Sumario:The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. Discoveries in the laboratory inform clinical trials which are the basis for improving the standard of care and are also the backbone for quality improvement. Clinical trials can be completed more rapidly by expanding trial enrollment to community sites. In this article we review some of the challenges in treating metastatic breast cancer with HER2-directed therapies and our strategies for incorporating our community partners into the research network.

Ejemplares similares